News


All series


All News

Approximately 46% of patients with breast cancer at high risk for recurrence but low genomic risk with the 70-gene breast cancer recurrence assay (MammaPrint) might not require adjuvant chemotherapy, according to prospective 5-year results of the MINDACT trial published in&nbsp;<em>The New England Journal of Medicine</em>.<sup>1</sup>

<p>Approximately four years after the FDA approval of two powerful new oral androgen-targeting agents for metastatic castration-resistant prostate cancer, an analysis&nbsp;heightened&nbsp;clinical awareness of the&nbsp;potential for both under-treatment and over-treatment with abiraterone acetate, as well as potential drug-drug interactions with both abiraterone acetate and enzalutamide.</p>

Priority review has been granted by the FDA for a new drug application (NDA) for rucaparib as a treatment for patients with&nbsp;<em>BRCA</em>-positive advanced ovarian cancer who have received at least 2 prior lines of chemotherapy, according to Clovis, the manufacturer of the PARP inhibitor.

Patients with renal cancer who underwent cytoreductive nephrectomy (CN) and targeted therapy (TT) had improved survival compared with patients who did not undergo the surgery, according to research from the Dana-Farber Cancer Institute and Brigham and Women&rsquo;s Hospital.<sup>1</sup>&nbsp;Historically, only 3 in 10 such patients undergo the procedure.

The extended release injection formulation of granisetron (Sustol) has been approved by the FDA for use in combination with other antiemetic therapies for the prevention of chemotherapy-induced nausea and vomiting (CINV), according to Heron Therapeutics, the manufacturer of the treatment.